RxDoctor Payments Data

Anna Sonstegard, MD

Dermatology · Sioux Falls, SDNPI 1902337298

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.3% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by AbbVie at 28.3% of the total. Reporting peaked in 2019 at $368 and has fallen 66.1% since, to $125 in 2025. That places this record below the midpoint for dermatology clinicians in SD, where the typical reported total is $1,250.

$1,290in general payments, 2019–2025

Across 17 payments — averaging $75.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$365
  • Johnson & Johnson$217
  • Novartis$152
  • Dermira, Inc.$125
  • Sanofi$125
  • Lilly USA, LLC$125
  • plus $181 from 2 others

What the payments were for

  • Food & beverage$1,19192%
  • Education$998%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,290 in reported general payments places this provider in the 50th percentile of 44 dermatology providers in South Dakota.

See all dermatology providers in South Dakota

Medicare billing

Part B allowed, 2024
$28,998
Medicare patients
161
Services billed
551

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx (2 Syringes)Secukinumab14$139,981
Taltz AutoinjectorIxekizumab11$137,288
Dupixent PenDupilumab22$83,011
Fluocinonide31$1,228
Clobetasol Propionate29$1,151
Ketoconazole36$948
Doxycycline Hyclate23$612
Clindamycin Phosphate12$491
Triamcinolone Acetonide50$444
MethotrexateMethotrexate Sodium14$254
Minoxidil17$171
Mupirocin15$127
Hydrocortisone25$123
Finasteride12$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisCosentyx (2 Syringes)$152$139,98114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 44 dermatology providers in South Dakota.

Other dermatology in Sioux Falls

See the full list for South Dakota

Where these figures come from

Is this you, or does something look wrong? →